Key Points
- Director James Mulay sold 15,600 shares of CG Oncology on April 17 at an average price of $73.01 for about $1.14 million, reducing his ownership by 50% (he now owns 15,600 shares).
- Analysts remain largely bullish with a consensus "Moderate Buy" and an average target of $79 (individual targets range up to $100), even as the stock trades near its 52-week high and the company reports negative EPS (recent quarter: -$0.51 vs. -$0.61 expected).
CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the completion of the transaction, the director owned 15,600 shares in the company, valued at approximately $1,138,956. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
James Mulay also recently made the following trade(s):
- On Monday, March 16th, James Mulay sold 1,964 shares of CG Oncology stock. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00.
CG Oncology Stock Down 4.1%
NASDAQ CGON opened at $70.40 on Tuesday. CG Oncology, Inc. has a 52-week low of $19.91 and a 52-week high of $73.56. The business's 50-day moving average price is $62.71 and its 200 day moving average price is $50.82. The firm has a market cap of $5.94 billion, a P/E ratio of -34.01 and a beta of 0.70.
CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. As a group, analysts anticipate that CG Oncology, Inc. will post -2.57 earnings per share for the current year.
Hedge Funds Weigh In On CG Oncology
A number of large investors have recently modified their holdings of CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology in the 4th quarter valued at approximately $27,000. Strengthening Families & Communities LLC acquired a new position in CG Oncology during the third quarter worth $40,000. Comerica Bank grew its holdings in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company's stock worth $43,000 after acquiring an additional 515 shares during the period. Picton Mahoney Asset Management purchased a new position in CG Oncology in the fourth quarter worth $118,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company's stock worth $163,000 after acquiring an additional 972 shares in the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. The Goldman Sachs Group restated a "buy" rating and set a $82.00 price target on shares of CG Oncology in a research note on Monday, January 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a research report on Wednesday, January 21st. Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a research note on Friday, January 9th. HC Wainwright upped their price objective on shares of CG Oncology from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. Finally, Royal Bank Of Canada raised their target price on shares of CG Oncology from $61.00 to $73.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, CG Oncology has a consensus rating of "Moderate Buy" and an average target price of $79.00.
Check Out Our Latest Report on CG Oncology
CG Oncology Company Profile
(
Get Free Report)
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
